Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | CES2 | O00748 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 2/20 | 0.32 |
| ▸ | RECQL | P46063 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.31 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25754332 | 0.87 | HDAC6 (0.32) | SMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL25754333 | 0.86 | KDM4E (0.42) | KDM4ESMN1; SMN2ALDH1A1TSHRGAA | |
| SCHEMBL25754343 | 0.85 | SAT1 (0.37) | CYP1A2CYP2C19CES2KDM4ESMN1; SMN2 | |
| SCHEMBL25754218 | 0.84 | CES2 (0.47) | CES2ALDH1A1TSHREPHX2MEN1 | |
| SCHEMBL25754329 | 0.82 | PAOX (0.38) | CYP1A2CYP2C19SMN1; SMN2LMNATSHR | |
| SCHEMBL25754339 | 0.82 | EPHX2 (0.34) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E | |
| SCHEMBL25754318 | 0.82 | HDAC6 (0.41) | CYP1A2CYP2C19SMN1; SMN2LMNATSHR | |
| SCHEMBL25754334 | 0.82 | KDM4E (0.34) | KDM4ESMN1; SMN2ALDH1A1LMNATSHR | |
| SCHEMBL25754320 | 0.80 | — | — | |
| SCHEMBL25754310 | 0.80 | KDM4E (0.36) | CYP1A2CYP3A4CYP2D6CYP2C19KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | EUBULUS BIOTHERAPEUTICS (HONG KONG) LIMITED (HK) | 2023-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230210999-A1 | TARGETED PROTEASE DEGRADATION (TED) PLATFORM | UCHL3, UBE2L3, ADAM33 | CYP1A2 3367/4885CYP3A4 3673/4885CYP2D6 3633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.